Connect Biopharma Holdings (CNTB)

• Market cap: $130M
• 1 day: -3.4%
• 5 days: -6.13%
• 1 month: -16.39%
• 3 months: -26.3%
• 6 months: -15.68%
• Year to date: -21.03%
• 1 year: 103.08%
• 5 years: -88.54%
• 10 years: -89.24%
• Sector: Healthcare
• Industry: Biotechnology

About: Connect Biopharma Holdings Ltd is a clinical-stage biopharmaceutical company dedicated to transforming care for asthma and chronic obstructive pulmonary disease (COPD). The company is advancing rademikibart, a next-generation antibody designed to target interleukin-4-receptor alpha. It is currently conducting clinical studies of rademikibart for the treatment of acute exacerbations of asthma and COPD. The company operates in one operating segment: treatment of respiratory diseases.

Employees: 64